celecoxib + gemcitabine + irinotecan

The combination of celecoxib + gemcitabine + irinotecan has been studied primarily for the treatment of inoperable pancreatic cancer. This combination therapy brings together three distinct medications with different mechanisms of action to create a potentially more effective treatment approach. ## Drug Information Celecoxib (Celebrex) is a selective cyclooxygenase-2 (COX-2) inhibitor that targets the COX-2 enzyme, which is overexpressed in many pancreatic cancers[1][3]. Gemcitabine (Gemzar) is a nucleoside analog that interferes with DNA synthesis, while irinotecan (Camptosar) is a topoisomerase I inhibitor that prevents DNA unwinding during replication[1][7]. Clinical trials have shown encouraging results with this combination. In one study involving 11 patients with inoperable pancreatic cancer, the treatment led to pain relief, improved performance status, and decreases in tumor markers such as CA 19-9 and carcinoembryonic antigen (CEA)[1][7]. A phase II trial confirmed that this combination is an active therapy for inoperable pancreatic cancer, with marked reductions in CA19-9 observed in patients[4][9]. The dosing regimen typically involves gemcitabine at 1000mg/m², irinotecan at 100mg/m² on days 1 and 8 of a 21-day cycle, and celecoxib at 400mg twice daily continuously throughout treatment[8]. ## Clinical Evidence The rationale for adding celecoxib to the chemotherapy combination is based on findings that COX-2 expression is increased at both RNA and protein levels in most pancreatic carcinomas compared to normal tissue[7]. In vitro studies demonstrated that specific inhibition of COX-2 produced a dose-dependent inhibition of cell proliferation in pancreatic cell lines[7]. While the gemcitabine + irinotecan combination has shown limited survival benefit in some studies (median survival of 6.3-6.6 months)[7], the addition of celecoxib appears to enhance clinical benefits in terms of symptom control and disease stabilization. However, it's worth noting that not all studies have shown benefits from adding celecoxib to chemotherapy regimens. In a randomized phase II trial for non-small-cell lung cancer, the addition of celecoxib to chemotherapy did not appear to enhance efficacy or improve patient-reported symptoms[6]. The combination has also been studied in patients with biliary cancer, where it was noted to improve performance status, provide pain relief, and decrease levels of CEA and CA 19-9[2]. This treatment approach represents an attempt at targeted therapy for pancreatic cancer, combining conventional chemotherapeutic agents with a selective inhibitor of a pathway implicated in pancreatic cancer growth and progression.